Roche’s arthritis drug RoActemra receives EMA’s approval to treat children suffering from rare form of childhood arthritis

June 10, 2013 | By Márcio Barra

RoActemra (tocilizumab), was the first monoclonal antibody that targets the interleukin-6 (IL-6) receptor, for the treatment of Rheumatoid Arthritis, and was approved by EMA in 2009. IL-6 is a chemical messenger in the body responsible for the painful and persistent system-wide inflammation that people with RA suffer.

In a statement released by Roche, RoActemra can now be used to treat children, who have not responded to treatment with methotrexate (MTX), an anti-rheumatic drug, either alone or in combination with MTX, with polyarticular juvenile idiopathic arthritis.

Roche stated that this is the second paediatric indication for RoActemra, following a 2011 approval for systemic juvenile idiopathic arthritis. Hal Barron, Roche’s chief medical officer, said the approval comes earlier than expected, just one month following the positive opinion from the EMA’s Committee for Medicinal Products for Human Use.



Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: